Welcome to our dedicated page for Angiodynamics news (Ticker: ANGO), a resource for investors and traders seeking the latest updates and insights on Angiodynamics stock.
AngioDynamics Inc. (ANGO) develops minimally invasive medical devices for oncology, vascular, and surgical treatments. This page aggregates official news and press releases about product innovations, financial performance, and strategic initiatives.
Investors and healthcare professionals will find timely updates on regulatory milestones, clinical study results, and market expansions. Content spans earnings announcements, technology partnerships, and FDA clearances relevant to interventional radiology and cancer treatment advancements.
All materials are sourced directly from the company and reputable financial publications. Bookmark this page for structured access to ANGO's evolving role in medical device innovation without promotional bias.
AngioDynamics, a medical technology leader, will present at the 21st Annual Needham Virtual Healthcare Conference on April 11, 2022, at 2:15 p.m. ET. Jim Clemmer, President and CEO, and Stephen Trowbridge, CFO, will represent the company. A live webcast of the presentation will be available on AngioDynamics' website, with a replay accessible post-event. The company specializes in technologies aimed at restoring healthy blood flow and improving patient quality of life, catering to unmet medical needs.
AngioDynamics, Inc. (NASDAQ: ANGO) will announce its third-quarter fiscal year 2022 financial results on April 7, 2022, before market opening. A conference call hosted by management will commence at 8:00 a.m. ET on the same day, allowing investors to discuss the financial outcomes. Participants can join the call via phone or access the live webcast from the AngioDynamics website. The call's recording will be available for playback shortly after its conclusion. AngioDynamics specializes in innovative, minimally invasive medical devices for various healthcare applications.
AngioDynamics, Inc. (NASDAQ: ANGO) announced that President and CEO Jim Clemmer and CFO Stephen Trowbridge will present at three investor conferences in March 2022. The conferences include:
- Oppenheimer Virtual Healthcare Conference: March 15, 2022, at 8:40 a.m. ET
- Barclays Global Healthcare Conference: March 16, 2022, in Miami Beach, FL, at 9:00 a.m. ET
- KeyBanc Virtual Life Sciences & MedTech Investor Forum: March 22, 2022, at 3:45 p.m. ET
Live webcasts will be available on the company's website.
AngioDynamics, Inc. (NASDAQ: ANGO), a leader in minimally invasive medical devices, announced that CEO Jim Clemmer will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 15, 2022, at 10:00 a.m. ET. This event is designed for BTIG clients. AngioDynamics specializes in devices for vascular access, peripheral vascular disease, and oncology, featuring a diverse product line including ablation systems and vascular access products. For more details, visit www.angiodynamics.com.
AngioDynamics reported fiscal Q2 2022 net sales of $78.3 million, up 7.6% year-over-year. Med Tech sales surged 36.4%, while Med Device grew 0.8%. Gross margin declined to 51.8%, impacted by a $4 million backlog due to ongoing supply chain challenges. The company recorded a GAAP loss per share of $0.21 and an adjusted loss of $0.02. Full market release of the AlphaVac device occurred post-quarter. Fiscal year 2022 revenue guidance remains at $310-315 million, but gross margin guidance was revised down to 52.0%-54.0%.
AngioDynamics, Inc. (NASDAQ: ANGO), a leader in minimally invasive medical devices, announced that CEO Jim Clemmer and CFO Stephen Trowbridge will present at the 24th Annual Needham Virtual Growth Conference on January 10, 2022, at 2:00 p.m. ET. Investors can access a live webcast through the Company’s website, with a replay available afterward. AngioDynamics specializes in products for vascular access, peripheral vascular disease, and oncology, including market-leading ablation systems and vascular access products.
AngioDynamics, Inc. (NASDAQ: ANGO) announced it will report its second quarter financial results for fiscal year 2022 on January 6, 2022, prior to market open. The management will conduct a conference call at 8:00 a.m. ET on the same day to discuss these results. Interested participants can join by calling 1-877-407-0784 domestically or +1-201-689-8560 internationally, using passcode 13725681. The call will also be accessible via webcast on AngioDynamics' website, with a replay available later that day.
AngioDynamics reported fiscal 2022 Q1 results with net sales of $77.0 million, a 9.6% increase year-over-year. Gross margin rose to 52.1%, up 120 basis points. The company reported a GAAP loss per share of $0.18 and an adjusted loss of $0.02. Notably, Med Tech sales surged 68.0% to $17.6 million, driven by the Auryon platform. U.S. sales increased 19.1%, but international sales fell 22.4%. The company raised its FY2022 sales guidance to $310-$315 million.
AngioDynamics, Inc. (NASDAQ: ANGO) will announce its first-quarter fiscal year 2022 financial results on
AngioDynamics (NASDAQ: ANGO) announced that CEO Jim Clemmer and CFO Stephen Trowbridge will present at the 41st Annual Canaccord Genuity Virtual Growth Conference on August 11, 2021, at 9:00 a.m. ET. A live webcast of the presentation will be available on the company’s website and can be replayed afterward. AngioDynamics specializes in minimally invasive medical devices for vascular access and oncology, offering a range of products including ablation systems and vascular access solutions.
FAQ
What is the current stock price of Angiodynamics (ANGO)?
What is the market cap of Angiodynamics (ANGO)?
